urlscan.io logo urlscan.io
SecurityTrails logo

app.livestorm.co Open in urlscan Pro
54.155.223.238  Public Scan

Back to summary
Submitted URL: https://hcpconnects4.com/pub/cc?_ri_=X0Gzc2X%3DAQpglLjHJlTQGXa4MU1KsespkTA8BN0pzgdbg30W7L6Ezewp7hp0Rj3kbCaCMfozfPg5LOVXtp...
Effective URL: https://app.livestorm.co/moderna-na-medical/expert-panel-moderna-covid-19-vaccine-bivalent?type=detailed&tc=em_b29obfo&cc...
Submission: On October 05 via api from US — Scanned from DE

Form analysis 1 forms found in the DOM

<form class="base-form theme-webinar flex-col sm:flex-row inline-actions" novalidate="" data-v-1919a6ea="" data-v-11c29a75="" data-form-name="medical affairs|hcp|livestorm webinar registration form" data-form-type="signup form|non-dynamic form">
  <div class="gap-0 w-full sm:w-auto form-grid base-grid" data-v-1919a6ea="">
    <div class="mb-2 sm:mb-0 base-form-input" data-form-field="email" data-form-type="email" data-v-7159df02="" data-v-11c29a75="">
      <div class="content" data-v-7159df02=""><!---->
        <div class="input-wrapper" data-v-7159df02=""><!----><input class="base-input-large base-input base-form-style w-full" id="BaseFormInput:email:0" type="email" placeholder="you@example.com" data-recording-ignore="mask"
            data-v-7159df02=""><!----></div><!---->
        <div class="error" data-v-7159df02="">
          <div class="base-form-error text-14-medium text-red-600" data-v-7159df02="" style="display: none;"></div>
        </div>
      </div>
    </div>
  </div><!---->
  <div class="base-form-actions w-full md:w-auto justify-end" data-v-1919a6ea="">
    <div data-testid="submit-container" class="no-info" data-v-1919a6ea=""><button type="submit" class="base-button base-button-primary base-button-large md:w-auto submit-button" data-testid="baseform-submit-button" data-v-1919a6ea=""
        style="background-color: rgb(209, 52, 62); color: rgb(255, 255, 255);">
        <div class="button-wrapper"><!----><span class="content truncate">Register now</span><!----><!----></div>
      </button></div>
  </div><!---->
</form>

Text Content

With your agreement, we and our partners use cookies in order for our website to
work, for analytics and advertising purposes. You can enable or disable optional
cookies as desired. See our Privacy Policy for more information.  View our
partners
Learn More →Disagree and closeAgree and close
about-me variable

Moderna, Inc. invites you to their event


EXPERT PANEL DISCUSSES THE MODERNA COVID-19 VACCINE, BIVALENT

Select a date
Friday, October 7th 2022 - 7:00 PM (GMT)


Selected session begins in:

 * 2Days
 * 0Hours
 * 24Minutes
 * 26Seconds

Register now
Already registered?Resend my access link




Friday, October 7th 2022 - 7:00 PM (GMT)

About 1 hour

About this event

The Moderna COVID-19 Vaccine, Bivalent ushers in a new stage of protection,
targeting key Omicron variants and boosting durability. Please join a panel of
national experts on Friday, October 7, or Tuesday, October 11, for a live
virtual event discussing practical issues related to the bivalent vaccine.

Topics will include:

 * Current case, outcome, and vaccine data
 * Omicron variants, distinctions, and protection
 * ACIP bivalent vaccine recommendations
 * Patient FAQs and uptake strategies

AUTHORIZED USE

 * Emergency uses of the vaccine have not been approved or licensed by the FDA,
   but have been authorized by the FDA, under an Emergency Use Authorization
   (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The Moderna COVID-19
   Vaccine is authorized in individuals 6 months of age and older as a primary
   series. The Moderna COVID-19 Vaccine, Bivalent is authorized as a booster
   dose in individuals 18 years of age and older.
 * The EUA for these products is in effect for the duration of the COVID-19 EUA
   declaration justifying emergency use of the product, unless the declaration
   is terminated or the authorization is revoked sooner.
 * For more information on the EUA authorized uses of the vaccine, refer to the
   Fact Sheets for Healthcare Providers Administering Vaccine (Vaccine
   Providers) and Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Contraindications

Do not administer the vaccines to individuals with a known history of a severe
allergic reaction (e.g., anaphylaxis) to any component of the Moderna COVID-19
Vaccine or Moderna COVID-19 Vaccine, Bivalent.

Warnings and Precautions

 * Management of Acute Allergic Reactions: Appropriate medical treatment to
   manage immediate allergic reactions must be immediately available in the
   event an acute anaphylactic reaction occurs following administration of the
   vaccines. Monitor vaccine recipients for the occurrence of immediate adverse
   reactions according to the Centers for Disease Control and Prevention
   guidelines
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).
 * Myocarditis and Pericarditis: Postmarketing data demonstrate increased risks
   of myocarditis and pericarditis, particularly within 7 days following the
   second dose. The observed risk is highest in males 18 through 24 years of
   age. The CDC has published considerations related to myocarditis and
   pericarditis after vaccination, including for vaccination of individuals with
   a history of myocarditis or pericarditis
   (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).
 * Syncope (fainting): May occur in association with administration of
   injectable vaccines. Procedures should be in place to avoid injury from
   fainting.
 * Altered Immunocompetence: Immunocompromised persons, including individuals
   receiving immunosuppressive therapy, may have a diminished response to the
   vaccines.
 * Limitations of Vaccine Effectiveness: The vaccines may not protect all
   vaccine recipients.

Adverse Reactions

Adverse reactions reported in clinical trials for individuals 6 years of age and
older following administration of the Moderna COVID-19 Vaccine include pain at
the injection site, fatigue, headache, myalgia, chills, nausea/vomiting,
axillary swelling/tenderness, fever, erythema at the injection site, swelling at
the injection site, and arthralgia.

Adverse reactions in children 6 months through 5 years of age following
administration of Moderna COVID-19 Vaccine include pain at the injection site,
irritability/crying, fatigue, sleepiness, loss of appetite, headache, fever,
myalgia, chills, nausea/vomiting, axillary (or groin) swelling/tenderness,
arthralgia, erythema at the injection site, and swelling at the injection site.

Anaphylaxis and other severe allergic reactions, myocarditis, pericarditis, and
syncope have been reported following administration of the Moderna COVID-19
Vaccine during mass vaccination outside of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent
with more widespread use of the vaccines.

Reporting Adverse Events and Vaccine Administration Errors

The vaccination provider is responsible for mandatory reporting of the following
to the Vaccine Adverse Event Reporting System (VAERS):

 * vaccine administration errors whether or not associated with an adverse event
 * serious adverse events (irrespective of attribution to vaccination)
 * cases of myocarditis
 * cases of pericarditis
 * cases of Multisystem Inflammatory Syndrome (MIS)
 * cases of COVID-19 that result in hospitalization or death

Complete and submit reports to VAERS online at
https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to
VAERS, call 1-800-822-7967. Reports should include the words “Moderna COVID-19
Vaccine EUA” or “Moderna COVID-19 Vaccine, Bivalent EUA” in the description
section of the report.

Report to ModernaTX, Inc. by calling 1-866-MODERNA (1-866-663-3762) or provide a
copy of the VAERS form by faxing 1-866-599-1342 or emailing
ModernaPV@modernatx.com.

Please see the Vaccine Fact Sheets for Healthcare Providers Administering
Vaccine (Vaccine Providers) and Full Prescribing Information for:

 * Bivalent Booster dose for 18+ years
 * Primary series for 12+
 * Primary series for 6 - 11 years
 * Primary series for 6 months - 5 years




US-COV-2200426

Hosted by

 * Guest speaker
   
   G
   Dr. Gary Marshall Chief, Division of Pediatric Infectious Diseases @ Norton
   Children’s and the University of Louisville School of Medicine
   
   
   

 * Guest speaker
   
   G
   Dr. Jeffrey Goad Tenured Professor, Pharmacy Practice Chair @ Chapman
   University School of Pharmacy
   
   
   

 * Guest speaker
   
   G
   Dr. Lauren Angelo Associate Dean for Academic Affairs and Associate Professor
   of Pharmacy Practice @ Rosalind Franklin University College of Pharmacy
   
   
   

 * Guest speaker
   
   G
   Dr. Wendy Wright Family Nurse Practitioner @ Wright & Associates Family
   Healthcare
   
   
   


MODERNA, INC.

Deliver on the promise of mRNA science to create a new generation of
transformative medicines.


Share this event

 * 
 * 
 * 
 * 


Copy permalink
Powered by